Skip to content
Urban Fortune Today

Patients Stopping Anti-Obesity Injections Regain Pounds Far More Rapidly Compared to Dieters

Image of pharmaceutical injection and weighing machine
Obesity treatment involves long-term strategies.

Fresh analysis reveals that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who stop traditional diet and exercise regimens.

Published data in a major medical journal points out that while overweight individuals can lose about a fifth of their body weight while on the medication, the mass is regained at an estimated rate of 0.8 kg per month once they quit.

"Individuals purchasing such treatments should be cognizant of the potential of fast rebound weight gain when the therapy is stopped," warns researcher Dr. Susan Jebb.

Such speed of regain suggests a reversion to pre-treatment mass in about 18 months.

Analyzing Approaches

The study, which looked at dozens of studies involving over 9,000 of patients, contrasted the results of these new drugs with conventional dieting.

Researchers emphasize that individuals who shed pounds through diet and exercise usually see a slower weight regain—approximately 0.1 kg a month—after stopping.

The Reason for the Quick Rebound

Doctors suggest the mode of action of the drugs accounts for the amplified rebound.

The injections mimic a natural hormone called GLP-1, which helps regulate feelings of fullness.

"Sustained high doses of the hormone levels several times higher than the body's typical production might result in the system to generate a reduced amount of its own natural hormone, and could reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist.

"Stopping of this medication means hunger is uncontrolled, making excessive eating much more probable."

A Lifelong Condition?

The NHS suggest the injections for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.

A number of clinicians contend that, given the significant potential of weight regain, the treatment is often ongoing.

This opinion is reinforced by drug manufacturers, who say that the results "highlight the persistent nature of obesity," similar to managing diseases like high blood pressure.

Patient Experiences

People who have come off the medication explain a sudden return of cravings.

"I experienced something that goes on and I was suddenly starving," recalled one woman.

This difficulty is worsened if individuals have not established sustainable lifestyle or habit modifications during therapy.

Significant Use

Recent estimates indicate that millions of people in the UK have tried these injections in the past year, with demand continuing to grow.

  • Use is greater among women compared to males.
  • The middle-aged demographic shows the highest usage rates.
  • A large proportion obtain the drugs through private healthcare rather than public health services.

Finally, experts caution that while these medications are powerful tools for weight loss, they are not a standalone fix and maintained weight loss relies on integrated lifestyle support.

EM
The writer

Erik Mccarthy

Elena Mercer is a financial journalist specializing in urban wealth and lifestyle trends.

Urban Fortune Today

Type to search articles.